Enzymatic Wound Debridement Market To Reflect Growth Of $1.10 Billion By 2026 On The Back Of Product Approval Initiatives | Grand View Research Inc.

“Grand View Research, Inc. – Market Research And Consulting.”

The global enzymatic wound debridement market size is expected to reach USD 1.10 billion by 2026, registering a CAGR of 5.8%, as per a new report by Grand View Research Inc. The increasing incidence of chronic diseases and the introduction of technologically advanced products are factoring the enzymatic wound debridement market growth.

Researchers and industry players have undertaken several initiatives for developing technologically advanced products. Collagenase-based enzymatic wound debridement products are majorly used for chronic & acute wounds treatment.  Such products are gaining acceptance and has fueled the introduction of several technologically advanced products are being introduced in the market. For instance, NexoBrid (NXB), previously referred to as Debriding Gel Dressing (DGD)—which is derived from pineapple Bromelain group of enzymes-was introduced in 2017. NXB is an enzymatic wound debriding drug that can be effectively used in treating deep burn wounds.

New products are receiving government approvals for further commercialization.  For instance, in May 2019, Vericel Corporation entered into a supply agreement and exclusive license with MediWound Ltd. to capitalize their product called NexoBridin North America. The NexoBrid received approval in the U.S., European Union, and other international markets. 

Enzymatic Wound Debridement Market Report Highlights 

1. According to the WHO, an estimated 180 000 deaths occur every year due to severe burns inmiddle- and low-income countries and 30,000 people suffer new burns globally, some are severe enough to warrant immediate medical attention. Increasing number of accidents has resulted in a considerable growth of the market products

2. Market giants have entered into strategic alliances to enhance product innovation capabilities and stay ahead of the market competition. In June 2019, MediWound launched EscharEx® under the U.S. Clinical Development Program as the company’s topical biological drug candidate for hard-to-heal wounds. The company followed the pre-defined interim assessment of enzymatic and autolytic debridement to ensure the efficacy, safety, and clinical benefit of EscharEx

3. The acute wounds segment accounted for the highest revenue share in 2018. They include lacerations, burns abrasions, incisions, puncture wounds, etc. and is driven by the increasing number of burn injuries worldwide

4. Collagenase-based enzymatic wound debridement product segment dominated the market in 2018. Collagenase-based creams, ointments, and gels are widely used for debridement of necrotic tissue from pressure ulcers, venous leg ulcers, burn wounds, and partial-thickness burns

5. North America led the global market in 2018 due to rise in sports-related injuries and road accidents 

 “Would you Like/Try a Sample Report” Click the link below: https://www.grandviewresearch.com/industry-analysis/enzymatic-wound-debridement-market/request/rs1

Enzymatic Wound Debridement Market Segmentation

 Grand View Research has segmented the enzymatic wound debridement market report on the basis of product, type, end use, and region:

Enzymatic Wound Debridement Type Outlook (Revenue, USD Million, 2015 – 2026)

• Chronic Wounds

  • Diabetic Foot Ulcers

  • Pressure Ulcers

  • Venous Leg Ulcers

• Acute Wounds

  • Burn

  • Others

Enzymatic Wound Debridement Product Outlook (Revenue, USD Million, 2015 – 2026)

• Collagenase Product

• Papain Product

• Others

Enzymatic Wound Debridement End-use Outlook (Revenue, USD Million, 2015 – 2026)

• Hospitals

• Homecare

• Others

Enzymatic Wound Debridement Regional Outlook (Revenue, USD Million, 2015 – 2026)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

• Asia Pacific

  • China

  • Japan

• Latin America

  • Brazil

  • Mexico

• MEA

• South Africa

• Saudi Arabia

 Have Any Query? Ask Our Experts for More Details on Report: https://www.grandviewresearch.com/inquiry/6256/ibb

Browse Related Report @

Maggot Debridement Market – https://www.grandviewresearch.com/industry-analysis/maggot-debridement-market

Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.

About Grand View Research

Grand View Research is a market research and consulting company based in the State of California with headquarters in San Francisco. The company offers consulting services tailored for business organizations to assist them with understanding and exploring their potential on a large scale. At the same time, Grand View Research caters to the individual research needs to provide a customized research service.
Grand View Research is fully committed to offer the best research services in the Industry. Our dedicated team of experienced analysts offer full capability and potential to precisely understand your research needs.

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1888202951
Address:Grand View Research, Inc. 201 Spear Street 1100 San Francisco, CA 94105, United States
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/enzymatic-wound-debridement-market